Royalty Pharma annual debt-to-assets ratio
2019
2020
2021
2022
2023
2024
2025
Royalty Pharma Debt-to-Assets Ratio Growth & History (RPRX)
Royalty Pharma's debt-to-assets ratio was 0.46 for fiscal 2025.
View full Royalty Pharma company overviewRoyalty Pharma annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.46 | 0.04 | +9.44% |
| 2024 | 2024-12-31 | 0.42 | 0.04 | +11.54% |
| 2023 | 2023-12-31 | 0.37 | −0.05 | −11.51% |
| 2022 | 2022-12-31 | 0.42 | 0.02 | +4.47% |
| 2021 | 2021-12-31 | 0.41 | 0.04 | +11.58% |
| 2020 | 2020-12-31 | 0.36 | −0.14 | −27.54% |
| 2019 | 2019-12-31 | 0.50 | — | — |
Royalty Pharma quarterly debt-to-assets ratio
Q4.19
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.45 | 0.01 | +3.26% |
| Q1 2026 | 2026-03-31 | 0.45 | 0.02 | +4.70% |
| Q4 2025 | 2025-12-31 | 0.46 | 0.04 | +9.44% |
| Q3 2025 | 2025-09-30 | 0.46 | 0.04 | +9.91% |
| Q2 2025 | 2025-06-30 | 0.44 | 0.01 | +1.70% |
| Q1 2025 | 2025-03-31 | 0.43 | 0.05 | +13.67% |
| Q4 2024 | 2024-12-31 | 0.42 | 0.04 | +11.54% |
| Q3 2024 | 2024-09-30 | 0.42 | 0.03 | +9.04% |
| Q2 2024 | 2024-06-30 | 0.43 | 0.01 | +3.44% |
| Q1 2024 | 2024-03-31 | 0.38 | −0.04 | −8.75% |
| Q4 2023 | 2023-12-31 | 0.37 | −0.05 | −11.51% |
| Q3 2023 | 2023-09-30 | 0.39 | −0.02 | −3.90% |
| Q2 2023 | 2023-06-30 | 0.42 | 0.02 | +3.91% |
| Q1 2023 | 2023-03-31 | 0.42 | 0.01 | +2.08% |
| Q4 2022 | 2022-12-31 | 0.42 | 0.02 | +4.47% |
| Q3 2022 | 2022-09-30 | 0.40 | 0.00 | +0.63% |
| Q2 2022 | 2022-06-30 | 0.40 | 0.05 | +13.56% |
| Q1 2022 | 2022-03-31 | 0.41 | 0.04 | +11.71% |
| Q4 2021 | 2021-12-31 | 0.41 | 0.04 | +11.58% |
| Q3 2021 | 2021-09-30 | 0.40 | 0.04 | +10.02% |
| Q2 2021 | 2021-06-30 | 0.35 | −0.02 | −6.41% |
| Q1 2021 | 2021-03-31 | 0.37 | — | — |
| Q4 2020 | 2020-12-31 | 0.36 | −0.14 | −27.54% |
| Q3 2020 | 2020-09-30 | 0.36 | — | — |
| Q2 2020 | 2020-06-30 | 0.38 | — | — |
| Q4 2019 | 2019-12-31 | 0.50 | — | — |
Royalty Pharma debt-to-assets ratio trends
Over the last five fiscal years, Royalty Pharma's debt-to-assets ratio increased from 0.36 to 0.46, a change of 0.09. The latest reported quarter, Q2 2026, shows 0.45.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Royalty Pharma source filings ↗